Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Royalty Pharma Plc Cl A (RPRX)

Royalty Pharma Plc Cl A (RPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,519,690
  • Shares Outstanding, K 577,238
  • Annual Sales, $ 2,264 M
  • Annual Income, $ 858,980 K
  • EBIT $ 1,533 M
  • EBITDA $ 1,552 M
  • 60-Month Beta 0.42
  • Price/Sales 10.78
  • Price/Cash Flow 10.50
  • Price/Book 2.65

Options Overview Details

View History
  • Implied Volatility 54.20% (+16.12%)
  • Historical Volatility 18.85%
  • IV Percentile 88%
  • IV Rank 61.99%
  • IV High 75.80% on 01/14/26
  • IV Low 18.96% on 05/21/25
  • Expected Move (DTE 9) 0.23 (0.52%)
  • Put/Call Vol Ratio 0.07
  • Today's Volume 558
  • Volume Avg (30-Day) 1,074
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 13,310
  • Open Int (30-Day) 10,439
  • Expected Range 44.02 to 44.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.33
  • Number of Estimates 4
  • High Estimate 1.41
  • Low Estimate 1.13
  • Prior Year 1.15
  • Growth Rate Est. (year over year) +15.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.86 +13.87%
on 01/20/26
45.24 -2.19%
on 02/11/26
+4.08 (+10.16%)
since 01/09/26
3-Month
37.31 +18.60%
on 11/24/25
45.24 -2.19%
on 02/11/26
+5.29 (+13.58%)
since 11/11/25
52-Week
29.66 +49.19%
on 04/07/25
45.24 -2.19%
on 02/11/26
+12.00 (+37.21%)
since 02/11/25

Most Recent Stories

More News
Royalty Pharma (NASDAQ:RPRX) Reports Sales Below Analyst Estimates In Q4 CY2025 Earnings

Royalty Pharma (NASDAQ:RPRX) Reports Sales Below Analyst Estimates In Q4 CY2025 Earnings

RPRX : 44.25 (+0.09%)
Royalty Pharma Reports Q4 and Full Year 2025 Results

Portfolio Rece ipts of $874 million in Q4 2025 and $3,254 million for FY 2025 Portfolio Receipts growth of 18% in Q4 2025 and 16% for FY 2025 Net cas h provided by operating activities of...

RPRX : 44.25 (+0.09%)
What To Expect From Royalty Pharma’s (RPRX) Q4 Earnings

What To Expect From Royalty Pharma’s (RPRX) Q4 Earnings

RPRX : 44.25 (+0.09%)
3 Mid-Cap Stocks We Keep Off Our Radar

3 Mid-Cap Stocks We Keep Off Our Radar

RPRX : 44.25 (+0.09%)
IFF : 76.97 (+0.27%)
NLY : 22.81 (+0.80%)
3 Profitable Stocks with Open Questions

3 Profitable Stocks with Open Questions

RPRX : 44.25 (+0.09%)
JEF : 57.68 (-4.01%)
HZO : 28.74 (-1.30%)
Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2025 financial results on Wednesday, February 11, 2026...

RPRX : 44.25 (+0.09%)
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference

Royalty funding market reached record high of $10 billion in 2025, powered by synthetic royalties Royalty Pharma maintained industry leadership with announced transactions of $4.7 billion Multiple...

RPRX : 44.25 (+0.09%)
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva’s anti-IL-15 candidate, TEV-‘408 ...

RPRX : 44.25 (+0.09%)
TEVA : 34.31 (-0.17%)
Royalty Pharma Announces Dividend Increase

NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2026 of $0.235 per Class A ordinary...

RPRX : 44.25 (+0.09%)
Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Royalty Pharma (NASDAQ:RPRX)

Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Royalty Pharma (NASDAQ:RPRX)

RPRX : 44.25 (+0.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko...

See More

Key Turning Points

3rd Resistance Point 48.23
2nd Resistance Point 46.74
1st Resistance Point 45.49
Last Price 44.25
1st Support Level 42.75
2nd Support Level 41.26
3rd Support Level 40.01

See More

52-Week High 45.24
Last Price 44.25
Fibonacci 61.8% 39.29
Fibonacci 50% 37.45
Fibonacci 38.2% 35.61
52-Week Low 29.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar